Author: Zhang, XiZhen; Wang, XiaoDan; Zhao, DongHai; Meng, XiangYu; Zhao, XingHong; Yu, XiangHui; Kong, Wei
Title: Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine Document date: 2011_12_16
ID: xxypq3wd_1
Snippet: The development of an effective, safe, and affordable vaccine for human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is needed to control the worldwide HIV pandemic. At present, there is no vaccine against HIV approved for clinical use. There are three obstacles that hinder creation of an HIV-1 vaccine: viral diversity, immune system evasion, and the lack of appropriate animal models for vaccine evaluation [1] . A major a.....
Document: The development of an effective, safe, and affordable vaccine for human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is needed to control the worldwide HIV pandemic. At present, there is no vaccine against HIV approved for clinical use. There are three obstacles that hinder creation of an HIV-1 vaccine: viral diversity, immune system evasion, and the lack of appropriate animal models for vaccine evaluation [1] . A major approach used to overcome viral immune evasion is to exploit the conserved regions of HIV-1 proteins, for example, the conserved sites of envelope glycoprotein gp120 critical for binding to CD4 as well as co-receptors, or the envelope (transmembrane) protein gp41 co-receptor binding site [2] [3] [4] [5] . Inducing production of broadly reactive Mabs could potentially counteract HIV-1 diversity. These two potential solutions of HIV-1 vaccine development could potentially be realized by exploiting prophylactic HIV-1 virus-like particle (VLP) vaccines [6] .
Search related documents:
Co phrase search for related documents- animal model and binding site: 1, 2, 3, 4, 5, 6, 7
- animal model and co receptor: 1, 2
- animal model and HIV pandemic: 1
- animal model and HIV vaccine: 1, 2
- animal model and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- animal model and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- animal model and immune deficiency: 1, 2
- animal model and immune evasion: 1, 2, 3
- animal model and major approach: 1
- animal model and potential solution: 1
- animal model and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
- animal model and vaccine evaluation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- animal model and vaccine evaluation animal model: 1
- animal model and viral diversity: 1, 2, 3
- animal model and viral immune evasion: 1
- binding site and co receptor: 1, 2, 3, 4, 5
- binding site and HIV pandemic: 1, 2
- binding site and HIV vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- binding site and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
Co phrase search for related documents, hyperlinks ordered by date